ClinicalTrials.gg
CompletedNCT01587898Updated Nov 9, 2017Results posted

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

A Phase 2 interventional study of GSK1278863 and Placebo in Anaemia, sponsored by GlaxoSmithKline. Completed at 55 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-11-09.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
16th of 30
72 · median 76
Started
2012
with 2 others
Phase 2
10 of 30
none open now
Registered
3rd of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 16th largest by enrollment, is one of 3 that started in 2012, is one of 10 in phase 2, and was the 3rd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia associated with chronic kidney disease who are not taking rhEPO and are not undergoing dialysis. The range of Hgb values for study eligibility is 8.5-11.0 g/dL. Eligible subjects will be randomized in equal proportions to receive once daily (QD) placebo or GSK1278863 0.5 mg, 2 mg or 5 mg in a double-blind fashion.

Read the detailed description

This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia associated with chronic kidney disease who are not taking rhEPO and are not undergoing dialysis. The study consists of a screening phase of up to 2 weeks, a 4-week treatment phase and a 2-week follow-up phase. The range of Hgb values for study eligibility is 8.5-11.0 g/dL. Eligible subjects will be randomized in equal proportions to receive once daily (QD) placebo or GSK1278863 0.5 mg, 2 mg or 5 mg in a double-blind fashion. Study treatment will be stopped if Hgb values fall outside of the range pre-specified in the protocol.

This study aims to estimate the relationship between dose of GSK1278863 and Hgb response for correcting anemia in non-dialysis subjects with CKD who are not taking rhEPO (NDD). In addition, the study will characterize the effect of GSK1278863 on various pharmacokinetic/pharmacodynamic (PK/PD) markers, and will investigate the safety and tolerability of GSK1278863.

An early interim analysis of the Hgb data is planned after approximately 20 subjects from cohort 1 have completed 3 weeks of treatment. Depending upon the interim findings, a second cohort of subjects may be added to investigate an additional GSK1278863 dose arm. Recruitment to the first cohort will continue during the interim analysis.

A second interim analysis is planned after approximately 48 subjects from cohort 1 have completed 4 weeks treatment. The purpose of this interim is three-fold, to investigate whether a second cohort of subjects may be added, to facilitate early development of dose-response and PK/PD statistical models, and to generate interim results to facilitate design and dosing decisions for the next trial.

Subject completion is defined as completion of all study phases including the follow-up phase.

03

Conditions studied

  • Anaemia

Keywords

  • Anemia
  • Prolyl hydroxylase inhibitor
  • Hemoglobin
  • Chronic kidney disease
  • pharmacokinetics
  • recombinant human erythropoietin
  • GSK1278863
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age and weight: >/= 18 years of age and >/= 45 kg.
  2. Not routinely undergoing dialysis, regardless of the modality (either hemodialysis or peritoneal dialysis) or dialysis planned during the time the subject would be enrolled in the study.
  3. No current or prior rhEPO use within the past 7 weeks; e.g., epoetins (or their biosimilars), darbepoetin, Mircera (methoxy polyethylene glycol epoetin beta), peginesatide or their biosimilars..
  4. KDOQI CKD stages 3/4/5 defined by using the Modification of Diet for Renal Disease (MDRD).
  5. : Hgb concentrations 8.5-11.0 g/dL (inclusive) as outlined in Section 4.2.
  6. Vitamin B12: Above the lower limit of the reference range (may rescreen in 2 months).
  7. Folate: >/=2.0 ng/mL at Screening. May rescreen in a month.
  8. Ferritin: >/=40 ng/mL with the absence of microcytic or hypochromic RBCs.
  9. TSAT within the reference range.
  10. Iron replacement therapy: Stable maintenance dose of oral iron replacement therapy, if required, that will be maintained throughout the study. NOTE: IV iron replacement therapy is not allowed the two weeks prior to Screening through the end of the study (Week 6).
  11. : QTcB \<470 msec or QTcB \<480 msec in subjects with bundle branch block obtained at Screening Visit, based on Central Reader's interpretation.
  12. Females: Eligible to participate if she is of , and must agree to use approved methods from Screening until completion of the Follow-up Visit OR of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation of hysterectomy; or defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH)>40 MIU/ml and estradiol \<40 pg/ml is confirmatory]. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most types of HRT, at least 2 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
  13. Males: Must agree to use approved contraceptive methods from the time of Screening until completion of the Follow-up Visit.

Exclusion criteria

Exclusion Criteria:

  1. Dialysis: Planning to initiate dialysis during the study or who have a high potential for initiating dialysis during study participation.
  2. Renal transplant: Renal transplant anticipated or scheduled within the study time period or subjects with a functioning renal transplant.
  3. Total CPK: >5x the upper limit of the reference range.
  4. : Positive HIV antibody.
  5. History of myocardial infarction or acute coronary syndrome within the prior 6 months.
  6. History of stroke or TIAs.
  7. Heart failure: Class III/IV heart failure, as defined by the (NYHA) functional classification system.
  8. Hypertension: Poorly controlled hypertension, whether due to inadequate treatment, or lack of treatment, defined as DBP >100 mmHg or SBP>160 mmHg.
  9. Thrombotic disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention), or other thrombosis related condition) within the prior 6 months.
  10. Pulmonary hypertension: Known pulmonary hypertension and those at higher risk (than normally associated with CKD) for pre-existing elevation in pulmonary pressure (e.g., significant heart failure or lung disease requiring supplemental oxygen, or those with connective tissue diseases).
  11. Inflammatory disease: Chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease).
  12. Hematological disease: Any hematological disease including those affecting , the coagulation disorders (e.g., Protein C or S deficiency) or red blood cells (e.g. sickle cell anemia, myelodysplastic syndromes, hematological , myeloma, hemolytic anemia) or any other cause of anemia other than renal disease.
  13. Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [alkaline phosphatase, or AST > 2.0 x (ULN) or total > 1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study.
  14. Major surgery: Within the prior 12 weeks or planned during the study.
  15. Transfusion: Blood transfusion within the prior 12 weeks or an anticipated need for blood transfusion during the study.
  16. Ulcer and Active GI Bleeding: Evidence of active peptic, duodenal, or esophageal ulcer disease or active GI bleeding within the prior 12 weeks.
  17. Acute infection: Clinical evidence of acute infection or history of infection requiring intravenous (IV) antibiotic therapy the eight weeks prior to Screening through Day 1 (randomization).
  18. Malignancy: History of malignancy within 5 years of Screening or are receiving treatment for cancer or those with a strong family history of cancer (e.g., familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated.
  19. Hyperparathyroidism: hyperparathyroidism in the opinion of the Investigator, including subjects with parathyroid hormone (PTH) values ≥600 pg/mL.
  20. Eyes: History of proliferative retinopathy requiring treatment within the prior 12 months, or macular edema requiring treatment.
  21. Severe reactions: History of severe allergic or anaphylactic reactions or to in the product.
  22. Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Screening until the Follow-up Visit.
  23. Androgens: New androgen therapy or changes to pre-existing androgen regimen within prior 12 weeks.
  24. Prior investigational product exposure: The subject has participated in a clinical trial and has received an experimental investigational product within prior 30 days.
  25. Protocol compliance: Unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the protocol.
  26. Other conditions: Any condition which in the investigators opinion should exclude the subject from participating in the study.
  27. Pregnancy and lactation: Pregnant females as determined by positive urine hCG test, OR women who are lactating at Screening or during the trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    0.5mg GSK1278863

    Once daily

    Drug: GSK1278863

  • Experimental
    2mg GSK1278863

    Once daily

    Drug: GSK1278863

  • Experimental
    5mg GSK1278863

    Once daily

    Drug: GSK1278863

  • Experimental
    Placebo

    Once daily

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Modeled Hgb Change From Baseline Over 4 Weeks of Treatment

    Modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model. The model included fixed effects for baseline Hgb, treatment and a treatment by day interaction. Random effects was fitted in the intercept and the slope over time. All data up until investigational product discontinuation was included for Hgb efficacy evaluable participants; where efficacy evaluable was defined as having a baseline and at least 2 on-treatment Hgb assessments. Baseline was the average of Week -2 , Week -1 and Day 1 visits. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (average of Week -2, -1 and Day 1) and Week 4

Secondary outcomes

  1. Model-Adjusted Maximum Hgb Changes Over 4 Weeks

    Maximum Hgb change over 4 weeks was analyzed using an ANCOVA model with terms included for treatment and baseline Hgb value. Least square mean estimates and 95% CI for each treatment group were reported. Baseline was the average of Week -2 , Week -1 and Day 1 visits. The change from Baseline was calculated by subtracting the baseline value from the individual post-dose visit values.

    Time frame: Baseline (average of Week -2 , -1 and Day 1 visits) and 4 weeks

  2. Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb

    Number of participants achieving an increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb from baseline were reported. Entry into the study required a target stable Hgb of 8.5-11.0 g/dL. A stable Hgb value was confirmed from three Hgb values taken during the screening period at Week -2, Week -1 and Day 1 (randomization). The average of these three values was used for Baseline Hgb.

    Time frame: Up to 4 weeks

  3. Percentage of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb

    Percentage of participants achieving an increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb from baseline were reported. Entry into the study requires a target stable Hgb of 8.5-11.0 g/dL. A stable Hgb value was confirmed from three Hgb values taken during the screening period at Week -2, Week -1 and Day 1 (randomization). The average of these three values was used for Baseline Hgb.

    Time frame: Up to 4 weeks

  4. Number of Participants Who Reached Hgb Stopping Criteria

    The Hgb stopping criteria was defined as reaching to value \<8.0 g/dL, \>=8.0 - \<13.0 (\>= 2g/dL absolute Hgb change over 1 week ) or \>=13.0 g/dL. The number of participants who reached the Hgb stopping criteria of Hgb concentration were presented.

    Time frame: Up to Week 4

  5. Change From Baseline in Hepcidin at Week 2 and Week 4

    Blood samples for hepcidin were collected at Day 1 (pre-dose), Week 2 (approximately between 4 to 8 h) and Week 4 (pre-dose). Hepcidin is a regulator of iron metabolism. Baseline was the last pre-dose value on Day 1. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values. Where hepcidin values were missing because the value was below the quantification limit (BQL), the BQL value was imputed.

    Time frame: Baseline (Pre-dose on Day 1), Week 2 and 4

  6. Change From Baseline in Ferritin at Week 2 and Week 4

    Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4

  7. Change From Baseline in Transferrin at Week 2 and Week 4

    Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4

  8. Change From Baseline in Transferrin Saturation at Week 2 and Week 4

    Transferrin saturation was measured as a percentage, and is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation was the pre-dose value on Day 1. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4

  9. Change From Baseline in Total Iron Binding Capacity at Week 2 and Week 4

    Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4

  10. Change From Baseline in Total Iron at Week 2 and Week 4

    Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4

  11. Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 2 and Week 4

    Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4

  12. Change From Baseline in Hematocrit and Reticulocytes Over 4 Weeks

    Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, and 4

  13. Change From Baseline in Erythropoietin at Week 2 and Week 4

    Blood samples for erythropoietin were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1 and 3 h after this fist sample) and Week 4 (Pre-dose and 3 h post-dose). The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4

  14. Change From Baseline in Red Blood Cells Count Over 4 Weeks

    Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

    Time frame: Baseline (Day 1 pre-dose), week 1, 2, 3, 4

  15. Change From Baseline in Vascular Endothelial Growth Factor (VEGF) at Week 2 and Week 4

    Blood samples for VEGF were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1 and 3 h after this fist sample) and Week 4 (Pre-dose and 3 h post-dose). Baseline was the Day 1 pre-dose value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.

    Time frame: Baseline (Pre-dose), week 2 and 4

  16. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

    Time frame: Up to 6 weeks

  17. Number of Participants Discontinuing the Study Treatment Due to AEs

    AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. number of participants discontinuing the study treatment due to AEs.

    Time frame: Up to 6 weeks

  18. Absolute Values of Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) at Baseline (Day 1), Week 2, 4, and 6

    Clinical chemistry parameters including ALT, ALP, AST, CK were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).

    Time frame: Baseline (Day 1 pre-dose), Week 2, 4, and 6

  19. Absolute Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Baseline (Day 1), Week 2, 4, and 6

    Clinical chemistry parameters including albumin, apolipoprotein A1, apolipoprotein total, total protein were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).

    Time frame: Baseline (Day 1 pre-dose), Week 2, 4, and 6

  20. Absolute Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Baseline (Day 1), Week 2, 4, and 6

    Clinical chemistry parameters including calcium, chloride, cholesterol, glucose, inorganic phosphorus, potassium, sodium were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).

    Time frame: Baseline (Day 1 pre-dose), Week 2, 4, and 6

  21. Absolute Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Baseline (Day 1), Week 2, 4, and 6

    Clinical chemistry parameters including creatinine, direct bilirubin, indirect bilirubin, total bilirubin were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).

    Time frame: Baseline (Day 1 pre-dose), Week 2, 4, and 6

  22. Absolute Values of Urine Total Protein/Creatinine Ratio at Baseline (Day 1), Week 2, 4, and 6

    Absolute values of urine total protein/creatinine ratio at Baseline (Day 1), Week 2, 4, and follow-up (week 6) were reported.

    Time frame: Baseline (Day 1), Week 2, 4, and 6

  23. Change From Baseline Values of ALT, ALP, AST, CK at Week 2, 4, and 6

    Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the Baseline value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values. Change from Baseline values of ALT, AST, ALP and CK at Week 2, 4, and 6

    Time frame: Baseline (Day 1), Week 2, 4, and 6

  24. Change From Baseline Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Week 2, 4, and 6

    Baseline values were recorded on Day 1 (Pre dose). If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of albumin, apolipoprotein A1, apolipoprotein total, total protein at Week 2, 4, and 6 were reported.

    Time frame: Baseline (Day 1), Week 2, 4, and 6

  25. Change From Baseline Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Week 2, 4, and 6

    Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of calcium, chloride, cholesterol, glucose, inorganic phosphorus, potassium, sodium at Week 2, 4, and 6 were reported.

    Time frame: Baseline (Day 1), Week 2, 4, and 6

  26. Change From Baseline Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Week 2, 4, and 6

    Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of creatinine, direct bilirubin, indirect bilirubin, total bilirubin at Week 2, 4, and 6 were reported.

    Time frame: Baseline (Day 1), Week 2, 4, and 6

  27. Change From Baseline Values of Urine Total Protein/Creatinine Ratio at Week 2, 4, and 6

    Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of urine total protein/creatinine ratio at Week 2, 4, and 6 were reported.

    Time frame: Baseline (Day 1), Week 2, 4, and 6

  28. Absolute Values of Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, WBC Count (Absolute) at Baseline, Week 1, 2, 3, 4, and 6

    Hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet count, WBC count (absolute) were assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).

    Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6

  29. Absolute Values of Mean Corpuscle Volume at Baseline, Week 1, 2, 3, 4 and 6

    Hematology parameter mean corpuscle volume was assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).

    Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6

  30. Absolute Values of Mean Corpuscle Hgb Concentration at Baseline (Day 1), Week 1, 2, 3, 4, and 6

    Hematology parameter Mean Corpuscle Hgb Concentration was assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).

    Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6

  31. Absolute Values of Reticulocyte Count at Baseline (Day 1), Week 1, 2, 3, 4, and 6

    Hematology parameter reticulocyte were assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).

    Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6

  32. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, WBC Count (Absolute) at Week 1, 2, 3, 4, and 6

    Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet count, WBC count (absolute) at Week 1, 2, 3, 4, and 6 were reported.

    Time frame: Baseline (Day 1), Week 1, 2, 3, 4, and 6

  33. Change From Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6

    Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6 were reported.

    Time frame: Baseline (Day 1), Week 1, 2, 3, 4, and 6

  34. Change From Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6

    Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6 were reported.

    Time frame: Baseline (Day 1), Week 1, 2, 3, 4, and 6

  35. Absolute Values of Systolic Blood Pressure and Diastolic Blood Pressure Baseline, Week 1, Week 2, Week 3, Week 4 and Week 6

    Absolute values of systolic blood pressure and diastolic blood pressure Baseline (Day 1), Week 1, 2, 3, 4, and 6 as vital parameters were reported. Three measurements of systolic blood pressure and diastolic blood pressure were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff).

    Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6

  36. Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at Week 1, 2, 3, 4, and 6

    Three measurements of SBP and DBP were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff). Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in systolic blood pressure and diastolic blood pressure at Week 1, 2, 3, 4, and 6 were reported.

    Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6

  37. Absolute Values of Heart Rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6

    Absolute values of heart rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6 were reported as vital parameter. Three measurements of heart rate were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff).

    Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6

  38. Change From Baseline in Heart Rate at Week 1, 2, 3, 4, and 6

    Three measurements of heart rate were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff). Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. change from baseline in heart rate at Week 1, 2, 3, 4, and 6 were reported.

    Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6

  39. Absolute Electrocardiogram (ECG) Parameter Values at Baseline (Screening), Week 2, 4, and 6

    Full 12-lead ECGs were recorded in participants who were rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. Full 12-lead ECGs were recorded on the provided ECG machine that automatically calculates heart rate, PR, QRS, QT and QTc intervals. Absolute ECG parameters including PR interval, QT interval and QRS duration values at Baseline (Screening), Week 2, 4, and 6 were reported.

    Time frame: Baseline (Screening), Week 2, 4, and 6

  40. Change From Baseline in ECG Parameters at Week 2, 4 and 6

    Full 12-lead ECGs were recorded in participants who were rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. Full 12-lead ECGs were recorded on the provided ECG machine that automatically calculates heart rate, PR, QRS, QT and QTc intervals. Baseline ECG values were defined as measurements taken at screening. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.

    Time frame: Baseline (Screening), Week 2, 4, and 6

  41. Mean Maximum Plasma Concentration (Cmax) of GSK1278863 and GSK1278863 Metabolites

    Cmax of GSK1278863 and GSK1278863 metabolites (M1, M2, M3, M4, M5 and M6) were reported. For assessment of Pharmacokinetics parameters blood samples were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).

    Time frame: Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).

  42. Mean Steady State Area Under the Curve (AUC) of GSK1278863 and GSK1278863 Metabolites

    Mean Steady state AUC of GSK1278863 and GSK1278863 metabolites (M1, M2, M3, M4, M5 and M6) were reported. For pharmacokinetic parameter assessment blood samples were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this fist sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).

    Time frame: Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose)

07

Results

Posted Nov 9, 2017

Participant flow

The study was conducted at Canada, Germany, and United States between 29 May 2012 and 30 May 2013. A total of 282 participants were screened, 209 were screen failures and 73 eligible participants were randomized. Entry into the study requires a target stable hemoglobin (Hgb) of 8.5-11.0 gram per deciliter (g/dL).

Participant flow — Overall Study
MilestonePlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Started18171819
Completed14121617
Not completed4522
Withdrew: Adverse event1100
Withdrew: Protocol violation0211
Withdrew: Lost to follow-up0001
Withdrew: Withdrawal by subject2100
Withdrew: Met haemoglobin stopping criteria1110

Outcome measures

PrimaryModeled Hgb Change From Baseline Over 4 Weeks of Treatment

Modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model. The model included fixed effects for baseline Hgb, treatment and a treatment by day interaction. Random effects was fitted in the intercept and the slope over time. All data up until investigational product discontinuation was included for Hgb efficacy evaluable participants; where efficacy evaluable was defined as having a baseline and at least 2 on-treatment Hgb assessments. Baseline was the average of Week -2 , Week -1 and Day 1 visits. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (average of Week -2, -1 and Day 1) and Week 4
Reported as:
Mean · gram per decilitre (g/dL)
Modeled Hgb Change From Baseline Over 4 Weeks of Treatment
gram per decilitre (g/dL)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Modeled Hgb Change From Baseline Over 4 Weeks of Treatment-0.148 ± 0.19250.132 ± 0.22000.463 ± 0.21731.010 ± 0.2614
Statistical analysis
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.5888The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.6600The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.7999The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.2092The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.9996The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.7002The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.5536The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.0085The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.0021The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
  • Placebo vs GSK1278863, 0.5 mg vs GSK1278863, 2 mg vs GSK1278863, 5 mg · Mixed effects linear regression model · p = 0.2194The modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model.
SecondaryModel-Adjusted Maximum Hgb Changes Over 4 Weeks

Maximum Hgb change over 4 weeks was analyzed using an ANCOVA model with terms included for treatment and baseline Hgb value. Least square mean estimates and 95% CI for each treatment group were reported. Baseline was the average of Week -2 , Week -1 and Day 1 visits. The change from Baseline was calculated by subtracting the baseline value from the individual post-dose visit values.

Time frame:
Baseline (average of Week -2 , -1 and Day 1 visits) and 4 weeks
Reported as:
Least squares mean · g/dL
Model-Adjusted Maximum Hgb Changes Over 4 Weeks
g/dLPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Model-Adjusted Maximum Hgb Changes Over 4 Weeks0.153 ± 0.14760.137 ± 0.16090.474 ± 0.15321.069 ± 0.1527
SecondaryNumber of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb

Number of participants achieving an increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb from baseline were reported. Entry into the study required a target stable Hgb of 8.5-11.0 g/dL. A stable Hgb value was confirmed from three Hgb values taken during the screening period at Week -2, Week -1 and Day 1 (randomization). The average of these three values was used for Baseline Hgb.

Time frame:
Up to 4 weeks
Reported as:
Count of participants · Participants
Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb
ParticipantsPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Decrease/increase of < 0.5 g/dL1612124
Increase of >=0.5 g/dL34614
Increase of >=1 g/dL1129
Increase of >=1.5 g/dL0005
Increase of >=2 g/dL0001
SecondaryPercentage of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb

Percentage of participants achieving an increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb from baseline were reported. Entry into the study requires a target stable Hgb of 8.5-11.0 g/dL. A stable Hgb value was confirmed from three Hgb values taken during the screening period at Week -2, Week -1 and Day 1 (randomization). The average of these three values was used for Baseline Hgb.

Time frame:
Up to 4 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb
Percentage of participantsPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Decrease/increase of < 0.5 g/dL84756722
Increase of >=0.5 g/dL16253378
Increase of >=1 g/dL561150
Increase of >=1.5 g/dL00028
Increase of >=2 g/dL0006
SecondaryNumber of Participants Who Reached Hgb Stopping Criteria

The Hgb stopping criteria was defined as reaching to value \<8.0 g/dL, \>=8.0 - \<13.0 (\>= 2g/dL absolute Hgb change over 1 week ) or \>=13.0 g/dL. The number of participants who reached the Hgb stopping criteria of Hgb concentration were presented.

Time frame:
Up to Week 4
Reported as:
Count of participants · Participants
Number of Participants Who Reached Hgb Stopping Criteria
ParticipantsPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
<8.00010
>=8.0-<13.0 and >=2.0 decrease1000
>=8.0-<13.0 and >=2.0 increase0110
SecondaryChange From Baseline in Hepcidin at Week 2 and Week 4

Blood samples for hepcidin were collected at Day 1 (pre-dose), Week 2 (approximately between 4 to 8 h) and Week 4 (pre-dose). Hepcidin is a regulator of iron metabolism. Baseline was the last pre-dose value on Day 1. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values. Where hepcidin values were missing because the value was below the quantification limit (BQL), the BQL value was imputed.

Time frame:
Baseline (Pre-dose on Day 1), Week 2 and 4
Reported as:
Mean · Microgram per Litre (mcg/L)
Change From Baseline in Hepcidin at Week 2 and Week 4
Microgram per Litre (mcg/L)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Week 210.19 ± 88.535-23.46 ± 58.809-75.24 ± 88.862-120.31 ± 113.653
Week 4-2.62 ± 96.176-22.16 ± 120.138-77.34 ± 96.843-143.09 ± 119.617
SecondaryChange From Baseline in Ferritin at Week 2 and Week 4

Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (Day 1 Pre-dose), Week 2 and 4
Reported as:
Mean · mcg/L
Change From Baseline in Ferritin at Week 2 and Week 4
mcg/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Week 22.6 ± 50.49-20.0 ± 40.02-38.6 ± 70.20-58.8 ± 58.20
Week 4-24.3 ± 38.61-35.8 ± 54.68-8.2 ± 268.77-101.8 ± 91.07
SecondaryChange From Baseline in Transferrin at Week 2 and Week 4

Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (Day 1 Pre-dose), Week 2 and 4
Reported as:
Mean · Grams per litre (G/L)
Change From Baseline in Transferrin at Week 2 and Week 4
Grams per litre (G/L)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Week 2-0.017 ± 0.2551-0.100 ± 0.21940.153 ± 0.45560.141 ± 0.7335
Week 40.011 ± 0.26460.028 ± 0.27430.294 ± 0.34420.388 ± 0.3550
SecondaryChange From Baseline in Transferrin Saturation at Week 2 and Week 4

Transferrin saturation was measured as a percentage, and is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation was the pre-dose value on Day 1. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (Day 1 Pre-dose), Week 2 and 4
Reported as:
Mean · Percentage of transferrin saturation
Change From Baseline in Transferrin Saturation at Week 2 and Week 4
Percentage of transferrin saturationPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Week 20.7 ± 7.18-1.5 ± 4.16-3.7 ± 4.59-2.1 ± 6.51
Week 41.5 ± 6.08-3.1 ± 4.85-2.6 ± 6.18-3.4 ± 11.27
SecondaryChange From Baseline in Total Iron Binding Capacity at Week 2 and Week 4

Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (Day 1 Pre-dose), Week 2 and 4
Reported as:
Mean · Micromol per litre (micromol/L)
Change From Baseline in Total Iron Binding Capacity at Week 2 and Week 4
Micromol per litre (micromol/L)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Week 20.6 ± 5.63-1.6 ± 5.082.9 ± 3.305.9 ± 6.85
Week 4-0.5 ± 3.720.3 ± 6.345.1 ± 4.128.3 ± 5.54
SecondaryChange From Baseline in Total Iron at Week 2 and Week 4

Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (Day 1 Pre-dose), Week 2 and 4
Reported as:
Mean · micromol/L
Change From Baseline in Total Iron at Week 2 and Week 4
micromol/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Week 20.4 ± 3.71-1.1 ± 1.70-1.3 ± 2.970.4 ± 4.14
Week 40.6 ± 2.82-1.7 ± 3.31-0.4 ± 3.33-0.4 ± 6.10
SecondaryChange From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 2 and Week 4

Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (Day 1 Pre-dose), Week 2 and 4
Reported as:
Mean · miligram per litre (mg/L)
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 2 and Week 4
miligram per litre (mg/L)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Week 26.13 ± 32.2362.35 ± 6.973-1.00 ± 13.8784.32 ± 12.337
Week 40.21 ± 2.2120.65 ± 3.383-2.09 ± 11.7081.76 ± 9.378
SecondaryChange From Baseline in Hematocrit and Reticulocytes Over 4 Weeks

Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (Day 1 pre-dose), Week 1, 2, 3, and 4
Reported as:
Mean · Ratio
Change From Baseline in Hematocrit and Reticulocytes Over 4 Weeks
RatioPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Hematocrit, Week 1-0.15 ± 1.385-0.29 ± 1.976-0.35 ± 0.9410.39 ± 1.616
Hematocrit, Week 20.35 ± 1.8540.11 ± 1.5700.24 ± 1.6831.64 ± 2.103
Hematocrit, Week 3-0.24 ± 1.752-0.56 ± 1.1480.08 ± 1.4062.11 ± 2.257
Hematocrit, Week 4-0.50 ± 1.958-0.14 ± 1.2041.16 ± 2.5663.38 ± 2.052
Reticulocyte, Week 10.05 ± 0.4940.24 ± 0.4430.46 ± 0.7250.95 ± 0.626
Reticulocyte, Week 20.01 ± 0.4740.32 ± 0.4580.12 ± 0.6850.85 ± 0.633
Reticulocyte, Week 30.13 ± 0.4790.23 ± 0.3080.15 ± 0.6340.45 ± 0.525
Reticulocyte, Week 4-0.07 ± 0.3900.11 ± 0.375-0.07 ± 0.6600.49 ± 0.532
SecondaryChange From Baseline in Erythropoietin at Week 2 and Week 4

Blood samples for erythropoietin were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1 and 3 h after this fist sample) and Week 4 (Pre-dose and 3 h post-dose). The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (Day 1 Pre-dose), Week 2 and 4
Reported as:
Mean · Units per litre (U/L)
Change From Baseline in Erythropoietin at Week 2 and Week 4
Units per litre (U/L)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Week 2, 4-8 Hours Post-Dose0.721 ± 6.17731.022 ± 4.43193.622 ± 10.055113.267 ± 17.8580
Week 2, 5-9 Hours, Post Dose1.541 ± 6.68901.027 ± 4.38724.612 ± 10.949415.800 ± 18.5065
Week 2, 7-11 Hours, Post Dose0.437 ± 5.49350.538 ± 4.53826.630 ± 13.412020.100 ± 18.5656
Week 4, Pre-dose6.644 ± 17.64830.014 ± 3.99860.814 ± 6.88942.975 ± 7.5732
Week 4, 3 Hour Post-Dose6.346 ± 18.29781.039 ± 5.1686-0.075 ± 7.67792.102 ± 6.9180
SecondaryChange From Baseline in Red Blood Cells Count Over 4 Weeks

Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.

Time frame:
Baseline (Day 1 pre-dose), week 1, 2, 3, 4
Reported as:
Mean · 10^12 cells /L
Change From Baseline in Red Blood Cells Count Over 4 Weeks
10^12 cells /LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Week 1-0.01 ± 0.137-0.03 ± 0.181-0.03 ± 0.1130.04 ± 0.162
Week 20.02 ± 0.1810.03 ± 0.1600.01 ± 0.1650.14 ± 0.225
Week 3-0.03 ± 0.193-0.02 ± 0.136-0.02 ± 0.1470.16 ± 0.223
Week 4-0.05 ± 0.1810.01 ± 0.1450.09 ± 0.2540.33 ± 0.209
SecondaryChange From Baseline in Vascular Endothelial Growth Factor (VEGF) at Week 2 and Week 4

Blood samples for VEGF were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1 and 3 h after this fist sample) and Week 4 (Pre-dose and 3 h post-dose). Baseline was the Day 1 pre-dose value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.

Time frame:
Baseline (Pre-dose), week 2 and 4
Reported as:
Mean · Nanogram per litre (ng/L)
Change From Baseline in Vascular Endothelial Growth Factor (VEGF) at Week 2 and Week 4
Nanogram per litre (ng/L)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
WEEK 2, 4-8 HOURS POST-DOSE-12.09 ± 62.267-17.23 ± 56.519-19.55 ± 88.16720.38 ± 60.840
WEEK 2, 5-9 HOURS, POST DOSE-23.04 ± 104.309-18.21 ± 33.258-11.80 ± 100.7458.38 ± 39.975
WEEK 2, 7-11 HOURS, POST DOSE-41.40 ± 133.098-30.56 ± 58.602-17.88 ± 89.79314.40 ± 41.786
WEEK 4, PRE-DOSE-39.69 ± 114.26565.89 ± 161.068-7.47 ± 29.058-1.48 ± 30.874
WEEK 4, 3 HOUR POST-DOSE-43.33 ± 136.0480.77 ± 37.861-3.87 ± 36.5215.56 ± 41.400
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

Time frame:
Up to 6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Any AEs91056
Any SAEs1021
SecondaryNumber of Participants Discontinuing the Study Treatment Due to AEs

AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. number of participants discontinuing the study treatment due to AEs.

Time frame:
Up to 6 weeks
Reported as:
Count of participants · Participants
Number of Participants Discontinuing the Study Treatment Due to AEs
ParticipantsPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Number of Participants Discontinuing the Study Treatment Due to AEs1100
SecondaryAbsolute Values of Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) at Baseline (Day 1), Week 2, 4, and 6

Clinical chemistry parameters including ALT, ALP, AST, CK were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).

Time frame:
Baseline (Day 1 pre-dose), Week 2, 4, and 6
Reported as:
Mean · International Units per litre (IU/L)
Absolute Values of Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) at Baseline (Day 1), Week 2, 4, and 6
International Units per litre (IU/L)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
ALT, Day 111.8 ± 4.8513.8 ± 5.7418.8 ± 14.4016.2 ± 7.08
ALT, Week 210.8 ± 3.6812.4 ± 5.2820.1 ± 23.7914.1 ± 6.26
ALT, Week 411.4 ± 3.6114.6 ± 8.9222.2 ± 31.1213.2 ± 4.25
ALT, Week 610.1 ± 3.1114.9 ± 8.5716.9 ± 9.5516.5 ± 6.16
ALP, Day 186.6 ± 28.5095.6 ± 31.4797.7 ± 30.4885.9 ± 31.47
ALP, Week 284.3 ± 23.7391.5 ± 28.9092.2 ± 24.5687.2 ± 31.54
ALP, Week 484.1 ± 23.0290.4 ± 30.5792.6 ± 23.5190.1 ± 34.71
ALP, Week 683.9 ± 21.3289.2 ± 31.3887.1 ± 20.1392.4 ± 37.56
AST, Day 116.7 ± 4.5119.1 ± 5.0022.9 ± 14.7018.7 ± 6.68
AST, Week 216.1 ± 3.2117.5 ± 5.4226.1 ± 22.6619.0 ± 7.08
AST, Week 415.6 ± 2.4418.2 ± 5.3726.7 ± 29.9017.4 ± 6.06
AST, Week 615.2 ± 2.8120.1 ± 5.6921.4 ± 7.1219.8 ± 6.77
CK, Day 1101.6 ± 73.24132.4 ± 127.75159.4 ± 129.5694.4 ± 55.38
CK, Week 286.7 ± 51.04130.8 ± 124.04150.2 ± 92.89100.0 ± 78.25
CK, Week 494.4 ± 53.19114.2 ± 81.35136.4 ± 111.2283.1 ± 78.25
CK, Week 690.6 ± 60.11132.2 ± 97.34137.4 ± 82.22130.9 ± 269.29
SecondaryAbsolute Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Baseline (Day 1), Week 2, 4, and 6

Clinical chemistry parameters including albumin, apolipoprotein A1, apolipoprotein total, total protein were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).

Time frame:
Baseline (Day 1 pre-dose), Week 2, 4, and 6
Reported as:
Mean · G/L
Absolute Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Baseline (Day 1), Week 2, 4, and 6
G/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Albumin, Day 139.8 ± 3.3740.9 ± 4.1239.7 ± 4.3839.8 ± 3.50
Albumin, Week 240.8 ± 3.9140.3 ± 5.3138.8 ± 4.3840.1 ± 3.54
Albumin, Week 440.6 ± 3.0041.3 ± 3.6839.1 ± 4.3339.2 ± 4.10
Albumin, Week 640.0 ± 4.2139.9 ± 5.0440.6 ± 3.2238.9 ± 3.33
Apolipoprotein A1, Day 11.481 ± 0.23521.515 ± 0.25461.461 ± 0.35611.572 ± 0.4178
Apolipoprotein A1, Week 21.418 ± 0.17321.472 ± 0.29011.469 ± 0.31421.370 ± 0.3831
Apolipoprotein A1, Week 41.482 ± 0.17121.452 ± 0.30341.436 ± 0.25531.405 ± 0.4564
Apolipoprotein A1, Week 61.472 ± 0.19211.501 ± 0.24821.468 ± 0.25141.492 ± 0.4378
Apolipoprotein Total, Day 10.794 ± 0.22780.936 ± 0.26450.788 ± 0.24190.792 ± 0.2884
Apolipoprotein Total, Week 20.754 ± 0.21900.901 ± 0.25290.733 ± 0.19210.751 ± 0.3278
Apolipoprotein Total, Week 40.720 ± 0.17270.888 ± 0.25350.724 ± 0.20710.743 ± 0.2921
Apolipoprotein Total, Week 60.732 ± 0.18430.872 ± 0.20620.757 ± 0.22860.776 ± 0.3036
Total Protein, Day 169.4 ± 8.5371.1 ± 6.4168.5 ± 5.5067.7 ± 4.90
Total Protein, Week 270.8 ± 9.2470.1 ± 7.8166.4 ± 4.2668.3 ± 4.54
Total Protein, Week 470.7 ± 10.8771.8 ± 6.5366.9 ± 4.2467.6 ± 6.77
Total Protein, Week 669.8 ± 9.8369.7 ± 8.3668.3 ± 3.2666.9 ± 4.88
SecondaryAbsolute Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Baseline (Day 1), Week 2, 4, and 6

Clinical chemistry parameters including calcium, chloride, cholesterol, glucose, inorganic phosphorus, potassium, sodium were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).

Time frame:
Baseline (Day 1 pre-dose), Week 2, 4, and 6
Reported as:
Mean · Millimol per Litre (MMOL/L)
Absolute Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Baseline (Day 1), Week 2, 4, and 6
Millimol per Litre (MMOL/L)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Calcium, Day 12.258 ± 0.10262.296 ± 0.14042.259 ± 0.15372.335 ± 0.1351
Calcium, Week 22.299 ± 0.09152.298 ± 0.14722.331 ± 0.12932.347 ± 0.1510
Calcium, Week 42.274 ± 0.08722.302 ± 0.12342.301 ± 0.09222.348 ± 0.1610
Calcium, Week 62.255 ± 0.10492.331 ± 0.18612.309 ± 0.14892.322 ± 0.1360
Chloride, Day 1105.4 ± 3.05103.1 ± 3.83103.9 ± 5.98104.7 ± 5.11
Chloride, Week 2105.6 ± 2.69104.2 ± 4.31103.6 ± 6.31103.1 ± 5.90
Chloride, Week 4106.6 ± 3.91105.0 ± 4.43104.0 ± 5.56106.4 ± 3.97
Chloride, Week 6106.7 ± 3.52105.3 ± 3.99103.8 ± 6.19104.2 ± 3.90
Cholesterol, Day 14.147 ± 0.90854.632 ± 1.21604.088 ± 1.14244.411 ± 1.4333
Cholesterol, Week 23.997 ± 0.75474.623 ± 1.14693.800 ± 0.87874.282 ± 1.5566
Cholesterol, Week 43.893 ± 0.58804.448 ± 1.08083.776 ± 0.92764.091 ± 1.4236
Cholesterol, Week 63.944 ± 0.66134.520 ± 1.07753.928 ± 1.02534.406 ± 1.4561
Glucose, Day 16.97 ± 3.0829.11 ± 5.1899.46 ± 4.8407.75 ± 3.077
Glucose, Week 26.78 ± 3.3338.48 ± 4.3229.64 ± 4.1609.42 ± 6.596
Glucose, Week 46.49 ± 3.2469.03 ± 4.9408.63 ± 2.6536.71 ± 2.162
Glucose, Week 68.88 ± 5.5348.34 ± 3.5039.14 ± 4.2437.81 ± 3.506
Phosphorus, inorganic, Day 11.325 ± 0.26861.364 ± 0.25451.403 ± 0.31651.313 ± 0.2655
Phosphorus, inorganic, Week 21.309 ± 0.21161.421 ± 0.28481.435 ± 0.32971.285 ± 0.2871
Phosphorus, inorganic, Week 41.293 ± 0.22351.388 ± 0.29221.403 ± 0.26601.244 ± 0.2674
Phosphorus, inorganic, Week 61.319 ± 0.28101.345 ± 0.25271.366 ± 0.35671.203 ± 0.2322
Potassium, Day 14.57 ± 0.4524.65 ± 0.6324.65 ± 0.4894.63 ± 0.498
Potassium, Week 24.67 ± 0.4104.61 ± 0.7034.71 ± 0.6274.62 ± 0.593
Potassium, Week 44.54 ± 0.4604.61 ± 0.4684.56 ± 0.6714.42 ± 0.602
Potassium, Week 64.56 ± 0.5104.58 ± 0.4964.70 ± 0.5204.65 ± 0.624
Sodium, Day 1140.1 ± 2.65137.8 ± 3.00137.5 ± 3.92138.6 ± 3.45
Sodium, Week 2139.8 ± 2.60137.9 ± 2.00138.2 ± 3.88137.5 ± 4.62
Sodium, Week 4140.6 ± 3.13139.2 ± 2.65138.5 ± 3.59140.2 ± 3.53
Sodium, Week 6140.3 ± 2.46139.4 ± 2.13137.9 ± 4.65138.8 ± 2.83
SecondaryAbsolute Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Baseline (Day 1), Week 2, 4, and 6

Clinical chemistry parameters including creatinine, direct bilirubin, indirect bilirubin, total bilirubin were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).

Time frame:
Baseline (Day 1 pre-dose), Week 2, 4, and 6
Reported as:
Mean · Micromol/L
Absolute Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Baseline (Day 1), Week 2, 4, and 6
Micromol/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Creatinine, Day 1250.67 ± 110.117237.05 ± 91.762274.34 ± 146.092237.43 ± 128.461
Creatinine, Week 2235.92 ± 86.636245.16 ± 91.810267.07 ± 166.480217.84 ± 112.543
Creatinine, Week 4242.21 ± 106.796250.10 ± 101.583254.86 ± 149.148209.76 ± 109.374
Creatinine, Week 6244.43 ± 94.682238.07 ± 99.771254.86 ± 171.772219.50 ± 111.645
Direct bilirubin, Day 11.9 ± 1.112.1 ± 1.502.1 ± 1.111.6 ± 1.07
Direct bilirubin, Week 21.5 ± 1.121.7 ± 1.501.8 ± 0.662.1 ± 1.11
Direct bilirubin, Week 41.6 ± 0.851.8 ± 1.541.9 ± 0.861.9 ± 1.11
Direct bilirubin, Week 61.8 ± 1.441.8 ± 1.611.8 ± 0.682.1 ± 0.86
Indirect bilirubin, Day 14.0 ± 1.414.4 ± 1.464.4 ± 1.464.6 ± 1.34
Indirect bilirubin, Week 25.1 ± 2.014.5 ± 1.554.8 ± 1.744.6 ± 2.09
Indirect bilirubin, Week 44.3 ± 1.074.2 ± 1.304.8 ± 1.744.9 ± 1.75
Indirect bilirubin, Week 64.4 ± 1.675.0 ± 2.424.8 ± 1.243.8 ± 0.97
Total bilirubin, Day 15.9 ± 1.506.5 ± 0.876.5 ± 1.946.2 ± 1.62
Total bilirubin, Week 26.6 ± 2.096.1 ± 1.416.6 ± 1.976.7 ± 2.34
Total bilirubin, Week 45.9 ± 1.236.0 ± 1.156.7 ± 1.996.8 ± 2.35
Total bilirubin, Week 66.1 ± 1.366.8 ± 3.196.5 ± 1.375.9 ± 1.50
SecondaryAbsolute Values of Urine Total Protein/Creatinine Ratio at Baseline (Day 1), Week 2, 4, and 6

Absolute values of urine total protein/creatinine ratio at Baseline (Day 1), Week 2, 4, and follow-up (week 6) were reported.

Time frame:
Baseline (Day 1), Week 2, 4, and 6
Reported as:
Mean · mg/MMOL
Absolute Values of Urine Total Protein/Creatinine Ratio at Baseline (Day 1), Week 2, 4, and 6
mg/MMOLPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Urine Total Protein/Creatinine ratio, Day 1226.00 ± 268.727205.73 ± 366.100342.39 ± 518.396211.58 ± 241.306
Urine Total Protein/Creatinine ratio, Week 2170.41 ± 194.898207.82 ± 281.943194.14 ± 314.152149.08 ± 135.788
Urine Total Protein/Creatinine ratio, Week 4114.71 ± 130.867169.31 ± 262.401196.37 ± 326.453219.47 ± 280.924
Urine Total Protein/Creatinine ratio, Week 6232.80 ± 381.556162.81 ± 275.606175.16 ± 314.341160.01 ± 192.595
SecondaryChange From Baseline Values of ALT, ALP, AST, CK at Week 2, 4, and 6

Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the Baseline value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values. Change from Baseline values of ALT, AST, ALP and CK at Week 2, 4, and 6

Time frame:
Baseline (Day 1), Week 2, 4, and 6
Reported as:
Mean · IU/L
Change From Baseline Values of ALT, ALP, AST, CK at Week 2, 4, and 6
IU/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
ALT, Week 2-1.1 ± 2.89-1.2 ± 3.323.9 ± 21.85-1.9 ± 4.16
ALT, Week 40.1 ± 3.380.7 ± 6.796.0 ± 29.33-2.8 ± 7.68
ALT, Week 6-1.3 ± 3.090.7 ± 4.190.4 ± 7.510.5 ± 9.02
ALP, Week 20.8 ± 10.25-2.8 ± 12.11-1.2 ± 12.312.7 ± 10.52
ALP, Week 41.1 ± 8.92-4.8 ± 10.49-0.8 ± 18.422.6 ± 8.15
ALP, Week 6-1.9 ± 11.51-6.4 ± 14.19-5.7 ± 19.414.9 ± 13.40
AST, Week 2-0.9 ± 2.66-1.7 ± 3.514.7 ± 21.330.1 ± 3.92
AST, Week 4-1.3 ± 3.24-0.5 ± 4.375.1 ± 28.99-1.1 ± 4.70
AST, Week 6-1.6 ± 3.03-0.1 ± 5.92-0.3 ± 7.891.4 ± 4.66
CK, Week 2-18.7 ± 34.457.9 ± 137.741.2 ± 61.444.4 ± 53.00
CK, Week 4-21.4 ± 57.79-8.5 ± 90.90-12.6 ± 66.40-7.5 ± 39.31
CK, Week 6-19.1 ± 37.64-9.4 ± 97.00-5.1 ± 63.9340.4 ± 240.54
SecondaryChange From Baseline Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Week 2, 4, and 6

Baseline values were recorded on Day 1 (Pre dose). If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of albumin, apolipoprotein A1, apolipoprotein total, total protein at Week 2, 4, and 6 were reported.

Time frame:
Baseline (Day 1), Week 2, 4, and 6
Reported as:
Mean · G/L
Change From Baseline Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Week 2, 4, and 6
G/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Albumin, Week 20.7 ± 1.86-0.5 ± 1.92-0.9 ± 2.12-0.4 ± 2.12
Albumin, Week 40.4 ± 2.03-0.2 ± 2.08-0.6 ± 0.87-0.6 ± 2.71
Albumin, Week 60.2 ± 2.01-1.2 ± 2.080.1 ± 1.89-1.0 ± 2.65
Apolipoprotein A1, Week 2-0.045 ± 0.0887-0.063 ± 0.1386-0.023 ± 0.1754-0.197 ± 0.1641
Apolipoprotein A1, Week 4-0.011 ± 0.1144-0.061 ± 0.1198-0.025 ± 0.1932-0.163 ± 0.2133
Apolipoprotein A1, Week 6-0.009 ± 0.1287-0.026 ± 0.1408-0.011 ± 0.1618-0.076 ± 0.2743
Apolipoprotein total, Week 2-0.016 ± 0.0775-0.067 ± 0.1254-0.051 ± 0.1312-0.048 ± 0.1488
Apolipoprotein total, Week 4-0.036 ± 0.0954-0.051 ± 0.0910-0.055 ± 0.1852-0.024 ± 0.2123
Apolipoprotein total, Week 6-0.007 ± 0.0952-0.077 ± 0.16850.014 ± 0.21470.009 ± 0.2194
Total protein, Week 21.1 ± 3.04-0.7 ± 3.03-1.3 ± 3.64-0.2 ± 2.79
Total protein, Week 40.5 ± 3.18-0.1 ± 3.64-0.8 ± 2.650.2 ± 4.50
Total protein, Week 60.4 ± 2.73-1.5 ± 3.20-0.3 ± 2.44-0.6 ± 2.92
SecondaryChange From Baseline Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Week 2, 4, and 6

Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of calcium, chloride, cholesterol, glucose, inorganic phosphorus, potassium, sodium at Week 2, 4, and 6 were reported.

Time frame:
Baseline (Day 1), Week 2, 4, and 6
Reported as:
Mean · MMOL/L
Change From Baseline Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Week 2, 4, and 6
MMOL/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Calcium, Week 20.044 ± 0.06860.017 ± 0.07670.032 ± 0.09770.014 ± 0.0717
Calcium, Week 40.021 ± 0.10880.008 ± 0.0870-0.000 ± 0.06410.010 ± 0.0719
Calcium, Week 60.000 ± 0.10730.019 ± 0.1192-0.001 ± 0.0959-0.014 ± 0.0514
Chloride, Week 20.0 ± 3.590.9 ± 3.34-0.5 ± 4.95-1.5 ± 3.54
Chloride, Week 41.4 ± 2.841.8 ± 3.26-0.1 ± 3.430.9 ± 3.69
Chloride, Week 61.1 ± 2.951.9 ± 3.51-0.1 ± 3.94-1.3 ± 3.37
Cholesterol, Week 10.050 ± NA———
Cholesterol, Week 2-0.029 ± 0.2948-0.150 ± 0.5398-0.256 ± 0.3907-0.244 ± 0.6290
Cholesterol, Week 4-0.136 ± 0.3060-0.195 ± 0.4310-0.288 ± 0.6412-0.285 ± 0.8511
Cholesterol, Week 6-0.134 ± 0.4704-0.223 ± 0.7452-0.040 ± 0.84120.029 ± 0.7814
Glucose, Week 20.35 ± 3.025-0.59 ± 5.9400.13 ± 4.3751.67 ± 5.073
Glucose, Week 40.01 ± 2.893-0.21 ± 3.809-0.88 ± 3.968-0.51 ± 1.957
Glucose, Week 61.89 ± 3.9130.53 ± 3.725-0.57 ± 5.3390.59 ± 2.585
Inorganic phosphorus, Week 20.012 ± 0.14200.065 ± 0.15360.032 ± 0.22770.026 ± 0.2122
Inorganic phosphorus, Week 40.025 ± 0.17180.015 ± 0.17840.000 ± 0.2430-0.032 ± 0.1828
Inorganic phosphorus, Week 60.003 ± 0.3041-0.031 ± 0.1345-0.009 ± 0.2478-0.074 ± 0.1161
Potassium, Week 20.10 ± 0.4200.01 ± 0.5000.08 ± 0.558-0.02 ± 0.437
Potassium, Week 40.05 ± 0.470-0.02 ± 0.559-0.04 ± 0.488-0.23 ± 0.541
Potassium, Week 60.05 ± 0.601-0.05 ± 0.3850.06 ± 0.3460.01 ± 0.439
Sodium, Week 2-0.3 ± 2.420.1 ± 2.530.3 ± 2.80-0.9 ± 2.86
Sodium, Week 40.5 ± 3.781.6 ± 2.840.6 ± 2.961.3 ± 3.72
Sodium, Week 6-0.2 ± 2.291.3 ± 2.870.1 ± 3.04-0.1 ± 2.83
SecondaryChange From Baseline Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Week 2, 4, and 6

Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of creatinine, direct bilirubin, indirect bilirubin, total bilirubin at Week 2, 4, and 6 were reported.

Time frame:
Baseline (Day 1), Week 2, 4, and 6
Reported as:
Mean · Micromol/L
Change From Baseline Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Week 2, 4, and 6
Micromol/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Creatinine, Week 2-1.41 ± 22.366-0.99 ± 29.85410.78 ± 51.170-2.60 ± 18.802
Creatinine, Week 411.79 ± 20.8531.65 ± 18.800-1.44 ± 37.000-16.96 ± 23.293
Creatinine, Week 60.71 ± 46.295-5.01 ± 41.4777.24 ± 58.581-7.23 ± 29.816
Direct bilirubin, Week 2-0.5 ± 1.66-0.3 ± 1.99-0.4 ± 1.060.4 ± 1.27
Direct bilirubin, Week 4-0.6 ± 1.65-0.2 ± 1.74-0.2 ± 0.970.2 ± 1.20
Direct bilirubin, Week 6-0.4 ± 1.67-0.5 ± 1.13-0.4 ± 1.310.5 ± 0.87
Indirect bilirubin, Week 21.2 ± 2.130.1 ± 2.400.5 ± 1.33-0.1 ± 2.39
Indirect bilirubin, Week 40.4 ± 1.60-0.2 ± 2.170.5 ± 1.660.5 ± 1.66
Indirect bilirubin, Week 60.4 ± 2.090.9 ± 2.170.3 ± 1.61-0.7 ± 0.99
Total bilirubin, Week 20.7 ± 1.72-0.3 ± 1.030.1 ± 1.320.2 ± 2.33
Total bilirubin, Week 4-0.1 ± 1.23-0.5 ± 0.880.2 ± 1.860.7 ± 1.21
Total bilirubin, Week 60.0 ± 1.790.4 ± 2.53-0.1 ± 1.86-0.2 ± 0.66
SecondaryChange From Baseline Values of Urine Total Protein/Creatinine Ratio at Week 2, 4, and 6

Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of urine total protein/creatinine ratio at Week 2, 4, and 6 were reported.

Time frame:
Baseline (Day 1), Week 2, 4, and 6
Reported as:
Mean · MG/MMOL
Change From Baseline Values of Urine Total Protein/Creatinine Ratio at Week 2, 4, and 6
MG/MMOLPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Urine Total Protein/Creatinine ratio, Week 23.44 ± 39.792-38.83 ± 97.814-115.28 ± 265.028-77.98 ± 173.654
Urine Total Protein/Creatinine ratio, Week 4-20.56 ± 50.95317.43 ± 58.837-99.40 ± 209.67839.90 ± 86.729
Urine Total Protein/Creatinine ratio, Week 647.22 ± 185.115-26.73 ± 67.464-72.19 ± 187.792-41.40 ± 191.418
SecondaryAbsolute Values of Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, WBC Count (Absolute) at Baseline, Week 1, 2, 3, 4, and 6

Hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet count, WBC count (absolute) were assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).

Time frame:
Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Reported as:
Mean · 10^9 cells/L
Absolute Values of Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, WBC Count (Absolute) at Baseline, Week 1, 2, 3, 4, and 6
10^9 cells/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Basophils, Day 10.023 ± 0.01360.035 ± 0.02550.025 ± 0.02070.025 ± 0.0179
Basophils, Week 10.023 ± 0.01410.023 ± 0.00860.034 ± 0.02120.030 ± 0.0157
Basophils, Week 20.026 ± 0.01210.022 ± 0.01530.024 ± 0.01460.029 ± 0.0261
Basophils, Week 30.027 ± 0.02280.031 ± 0.01660.024 ± 0.01320.026 ± 0.0252
Basophils, Week 40.027 ± 0.02520.033 ± 0.03030.023 ± 0.01240.024 ± 0.0182
Basophils, Week 60.024 ± 0.01220.029 ± 0.01380.023 ± 0.01340.024 ± 0.0141
Eosinophils, Day 10.226 ± 0.25050.205 ± 0.08590.165 ± 0.10670.141 ± 0.0657
Eosinophils, Week 10.212 ± 0.22880.189 ± 0.10210.126 ± 0.10540.169 ± 0.0893
Eosinophils, Week 20.204 ± 0.26850.223 ± 0.12740.122 ± 0.08110.112 ± 0.0568
Eosinophils, Week 30.216 ± 0.21270.212 ± 0.12590.105 ± 0.08900.122 ± 0.0831
Eosinophils, Week 40.191 ± 0.20700.190 ± 0.09680.124 ± 0.09280.146 ± 0.0788
Eosinophils, Week 60.202 ± 0.25480.229 ± 0.12940.134 ± 0.09820.150 ± 0.1001
Lymphocytes, Day 11.844 ± 0.54151.662 ± 0.45521.473 ± 0.63321.602 ± 0.7284
Lymphocytes, Week 11.842 ± 0.70121.673 ± 0.52611.677 ± 0.79651.676 ± 0.4949
Lymphocytes, Week 21.629 ± 0.46861.741 ± 0.51921.356 ± 0.51371.533 ± 0.4984
Lymphocytes, Week 31.813 ± 0.55151.765 ± 0.53921.475 ± 0.62341.461 ± 0.4769
Lymphocytes, Week 41.795 ± 0.45171.736 ± 0.69191.428 ± 0.59801.330 ± 0.4753
Lymphocytes, Week 61.739 ± 0.49101.491 ± 0.51221.427 ± 0.63581.466 ± 0.4890
Monocytes, Day 10.384 ± 0.16020.345 ± 0.15160.319 ± 0.14050.373 ± 0.1056
Monocytes, Week 10.418 ± 0.17310.375 ± 0.11100.371 ± 0.15640.452 ± 0.1438
Monocytes, Week 20.400 ± 0.27300.339 ± 0.15330.305 ± 0.15430.383 ± 0.1502
Monocytes, Week 30.452 ± 0.22950.388 ± 0.14310.362 ± 0.21960.418 ± 0.1424
Monocytes, Week 40.305 ± 0.14200.388 ± 0.14400.365 ± 0.15150.367 ± 0.1030
Monocytes, Week 60.369 ± 0.10850.336 ± 0.13630.350 ± 0.18320.430 ± 0.2099
Total Neutrophils, Day 14.654 ± 2.49544.808 ± 1.85994.533 ± 1.41864.614 ± 1.5539
Total Neutrophils, Week 15.076 ± 4.09174.670 ± 1.46314.203 ± 1.17295.337 ± 1.8429
Total Neutrophils, Week 24.305 ± 2.14724.523 ± 1.93774.121 ± 1.15454.746 ± 1.6545
Total Neutrophils, Week 34.588 ± 1.79364.789 ± 1.82294.181 ± 1.19345.011 ± 2.1326
Total Neutrophils, Week 43.834 ± 1.40805.238 ± 1.83484.315 ± 1.54354.539 ± 2.1457
Total Neutrophils, Week 64.163 ± 1.69614.061 ± 1.05974.126 ± 1.00444.891 ± 2.2261
Platelet Count, Day 1199.9 ± 67.77229.9 ± 75.44219.2 ± 55.11223.5 ± 54.94
Platelet Count, Week 1204.8 ± 67.74219.8 ± 63.48225.8 ± 57.90238.8 ± 65.47
Platelet Count, Week 2211.3 ± 71.56230.1 ± 67.64209.7 ± 46.40229.9 ± 70.86
Platelet Count, Week 3211.5 ± 71.24237.3 ± 72.13208.5 ± 42.24224.6 ± 63.49
Platelet Count, Week 4184.6 ± 52.35255.8 ± 91.96215.3 ± 52.46240.5 ± 82.69
Platelet Count, Week 6195.1 ± 58.58207.9 ± 78.54217.9 ± 52.66227.1 ± 68.05
WBC count (absolute), Day 17.14 ± 2.5587.06 ± 2.3116.51 ± 1.5706.76 ± 1.747
WBC count (absolute), Week 17.56 ± 4.0016.92 ± 1.8856.42 ± 1.7407.67 ± 2.080
WBC count (absolute), Week 26.57 ± 2.3706.84 ± 2.4005.93 ± 1.0996.80 ± 1.798
WBC count (absolute), Week 37.11 ± 1.8407.18 ± 2.2316.14 ± 1.2757.04 ± 1.980
WBC count (absolute), Week 46.16 ± 1.4517.57 ± 2.3466.26 ± 1.6176.42 ± 2.106
WBC count (absolute), Week 66.50 ± 2.0756.14 ± 1.4546.06 ± 1.0446.97 ± 2.327
SecondaryAbsolute Values of Mean Corpuscle Volume at Baseline, Week 1, 2, 3, 4 and 6

Hematology parameter mean corpuscle volume was assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).

Time frame:
Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Reported as:
Mean · Femtolitre (FL)
Absolute Values of Mean Corpuscle Volume at Baseline, Week 1, 2, 3, 4 and 6
Femtolitre (FL)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Mean Corpuscle Volume, Day 193.8 ± 7.2992.4 ± 5.9094.8 ± 5.5094.2 ± 5.01
Mean Corpuscle Volume, Week 193.6 ± 7.0392.7 ± 6.6494.6 ± 5.9795.3 ± 3.56
Mean Corpuscle Volume, Week 293.9 ± 7.3492.8 ± 6.4095.5 ± 5.9395.4 ± 4.78
Mean Corpuscle Volume, Week 393.6 ± 7.4793.1 ± 6.6195.6 ± 5.7995.9 ± 4.87
Mean Corpuscle Volume, Week 493.9 ± 7.1693.4 ± 6.5896.1 ± 5.9295.7 ± 5.35
Mean Corpuscle Volume, Week 694.1 ± 7.2394.1 ± 4.4195.8 ± 5.9895.1 ± 4.81
SecondaryAbsolute Values of Mean Corpuscle Hgb Concentration at Baseline (Day 1), Week 1, 2, 3, 4, and 6

Hematology parameter Mean Corpuscle Hgb Concentration was assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).

Time frame:
Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Reported as:
Mean · G/L
Absolute Values of Mean Corpuscle Hgb Concentration at Baseline (Day 1), Week 1, 2, 3, 4, and 6
G/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Mean Corpuscle Hgb, Day 1328.6 ± 8.98330.9 ± 5.85330.2 ± 4.74328.4 ± 7.87
Mean Corpuscle Hgb, Week 1329.3 ± 7.47330.1 ± 7.90330.8 ± 6.69328.0 ± 8.46
Mean Corpuscle Hgb, Week 2327.3 ± 7.72329.9 ± 6.78331.3 ± 7.70326.5 ± 8.61
Mean Corpuscle Hgb, Week 3328.4 ± 5.56329.5 ± 7.53331.2 ± 6.12326.0 ± 8.67
Mean Corpuscle Hgb, Week 4329.6 ± 5.81328.8 ± 7.83329.6 ± 3.95326.1 ± 7.52
Mean Corpuscle Hgb, Week 6326.4 ± 7.36330.7 ± 8.70331.4 ± 5.74328.2 ± 8.17
SecondaryAbsolute Values of Reticulocyte Count at Baseline (Day 1), Week 1, 2, 3, 4, and 6

Hematology parameter reticulocyte were assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).

Time frame:
Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Reported as:
Mean · Ratio
Absolute Values of Reticulocyte Count at Baseline (Day 1), Week 1, 2, 3, 4, and 6
RatioPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Reticulocytes, Day 10.0183 ± 0.005840.0179 ± 0.004940.0208 ± 0.007470.0188 ± 0.00757
Reticulocytes, Week 10.0185 ± 0.006670.0198 ± 0.004460.0256 ± 0.010860.0284 ± 0.00635
Reticulocytes, Week 20.0178 ± 0.005580.0201 ± 0.004320.0224 ± 0.009930.0268 ± 0.00592
Reticulocytes, Week 30.0191 ± 0.006410.0189 ± 0.003880.0229 ± 0.009430.0232 ± 0.00570
Reticulocytes, Week 40.0174 ± 0.004860.0187 ± 0.006150.0203 ± 0.009050.0236 ± 0.00650
Reticulocytes, Week 60.0154 ± 0.004900.0196 ± 0.006810.0161 ± 0.008890.0142 ± 0.00700
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, WBC Count (Absolute) at Week 1, 2, 3, 4, and 6

Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet count, WBC count (absolute) at Week 1, 2, 3, 4, and 6 were reported.

Time frame:
Baseline (Day 1), Week 1, 2, 3, 4, and 6
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, WBC Count (Absolute) at Week 1, 2, 3, 4, and 6
10^9 cells/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Basophils, Week 1-0.000 ± 0.0153-0.011 ± 0.02280.008 ± 0.02600.003 ± 0.0214
Basophils, Week 20.004 ± 0.0145-0.013 ± 0.0300-0.001 ± 0.02020.004 ± 0.0336
Basophils, Week 30.004 ± 0.0229-0.005 ± 0.0273-0.001 ± 0.02180.002 ± 0.0221
Basophils, Week 40.005 ± 0.0241-0.000 ± 0.0310-0.003 ± 0.0239-0.001 ± 0.0232
Basophils, Week 6-0.000 ± 0.0157-0.003 ± 0.0276-0.003 ± 0.0230-0.001 ± 0.0169
Eosinophils, Week 1-0.014 ± 0.0724-0.014 ± 0.0896-0.029 ± 0.08410.023 ± 0.0774
Eosinophils, Week 2-0.033 ± 0.08210.021 ± 0.0914-0.013 ± 0.0919-0.031 ± 0.0636
Eosinophils, Week 3-0.014 ± 0.09080.012 ± 0.0893-0.040 ± 0.0553-0.018 ± 0.0695
Eosinophils, Week 4-0.020 ± 0.0855-0.004 ± 0.0971-0.028 ± 0.08810.011 ± 0.0818
Eosinophils, Week 6-0.012 ± 0.06380.034 ± 0.1241-0.018 ± 0.08710.009 ± 0.1048
Lymphocytes, Week 1-0.002 ± 0.43620.024 ± 0.33400.126 ± 0.38110.048 ± 0.3660
Lymphocytes, Week 2-0.234 ± 0.28740.062 ± 0.2353-0.176 ± 0.2424-0.036 ± 0.3978
Lymphocytes, Week 3-0.050 ± 0.28600.072 ± 0.3048-0.028 ± 0.36500.021 ± 0.3838
Lymphocytes, Week 4-0.137 ± 0.30110.030 ± 0.4575-0.082 ± 0.4047-0.081 ± 0.3471
Lymphocytes, Week 6-0.186 ± 0.3510-0.086 ± 0.3537-0.083 ± 0.33720.025 ± 0.3096
Monocytes, Week 10.034 ± 0.12880.042 ± 0.13590.032 ± 0.12580.096 ± 0.1305
Monocytes, Week 20.009 ± 0.17020.029 ± 0.0862-0.044 ± 0.14690.025 ± 0.1182
Monocytes, Week 30.060 ± 0.13300.075 ± 0.08590.015 ± 0.16340.054 ± 0.1240
Monocytes, Week 4-0.039 ± 0.11600.070 ± 0.09240.005 ± 0.1120-0.007 ± 0.1223
Monocytes, Week 6-0.012 ± 0.12450.006 ± 0.1212-0.010 ± 0.11600.066 ± 0.1579
Total Neutrophils, Week 10.422 ± 3.62060.027 ± 0.6517-0.362 ± 1.25270.457 ± 0.9942
Total Neutrophils, Week 20.155 ± 1.4350-0.217 ± 1.0644-0.400 ± 0.94700.086 ± 0.9817
Total Neutrophils, Week 30.014 ± 1.4591-0.101 ± 0.7464-0.373 ± 1.03190.335 ± 1.2442
Total Neutrophils, Week 4-0.394 ± 1.77570.493 ± 0.8534-0.239 ± 1.1614-0.148 ± 0.9234
Total Neutrophils, Week 6-0.229 ± 1.4571-0.278 ± 0.6628-0.428 ± 1.01100.215 ± 1.4295
Platelet count, Week 14.833 ± 21.3906-7.375 ± 23.51426.056 ± 31.662714.500 ± 19.4672
Platelet count, Week 216.375 ± 30.2189-10.500 ± 26.33730.200 ± 23.664912.941 ± 25.5721
Platelet count, Week 314.118 ± 44.4324-3.333 ± 21.8812-7.412 ± 26.86328.176 ± 29.1574
Platelet count, Week 4-1.357 ± 12.959112.417 ± 34.3973-0.563 ± 47.349722.500 ± 46.0232
Platelet count, Week 68.933 ± 16.1973-14.071 ± 44.07422.063 ± 21.386810.647 ± 31.0764
WBC count (absolute), Week 10.422 ± 3.41550.050 ± 0.7598-0.211 ± 1.58850.639 ± 0.9960
WBC count (absolute), Week 2-0.100 ± 1.5786-0.136 ± 1.1972-0.625 ± 1.08660.050 ± 1.0377
WBC count (absolute), Week 30.018 ± 1.56530.046 ± 0.8373-0.435 ± 1.05710.394 ± 1.3908
WBC count (absolute), Week 4-0.579 ± 1.74940.567 ± 0.8659-0.344 ± 1.4846-0.206 ± 1.1174
WBC count (absolute), Week 6-0.443 ± 1.5994-0.336 ± 0.8409-0.538 ± 1.08930.329 ± 1.4347
SecondaryChange From Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6

Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6 were reported.

Time frame:
Baseline (Day 1), Week 1, 2, 3, 4, and 6
Reported as:
Mean · FL
Change From Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6
FLPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Mean Corpuscle Volume, Week 1-0.222 ± 1.39560.125 ± 1.3601-0.222 ± 1.55510.278 ± 1.1275
Mean Corpuscle Volume, Week 20.188 ± 1.4705-0.214 ± 1.12170.125 ± 1.45490.944 ± 0.8726
Mean Corpuscle Volume, Week 3-0.235 ± 1.6405-0.231 ± 1.01270.118 ± 1.93271.176 ± 0.8828
Mean Corpuscle Volume, Week 4-0.143 ± 1.99450.083 ± 1.16450.188 ± 1.93971.188 ± 1.5152
Mean Corpuscle Volume, Week 6-0.133 ± 1.5523-0.071 ± 1.2688-0.125 ± 2.21740.353 ± 1.2719
SecondaryChange From Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6

Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6 were reported.

Time frame:
Baseline (Day 1), Week 1, 2, 3, 4, and 6
Reported as:
Mean · G/L
Change From Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6
G/LPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Mean Corpuscle Hgb Concentration, Week 10.667 ± 6.9367-0.688 ± 5.36310.222 ± 5.8767-0.389 ± 6.3165
Mean Corpuscle Hgb Concentration, Week 2-0.875 ± 8.8835-0.214 ± 5.92490.750 ± 8.2341-2.111 ± 5.7792
Mean Corpuscle Hgb Concentration, Week 30.647 ± 7.7938-0.462 ± 6.43710.294 ± 8.6658-2.588 ± 8.5225
Mean Corpuscle Hgb Concentration, Week 42.429 ± 8.2808-1.417 ± 5.0355-1.375 ± 6.7318-2.625 ± 5.5121
Mean Corpuscle Hgb Concentration, Week 6-1.200 ± 7.1534-1.714 ± 8.32450.438 ± 7.8568-0.353 ± 8.1620
SecondaryAbsolute Values of Systolic Blood Pressure and Diastolic Blood Pressure Baseline, Week 1, Week 2, Week 3, Week 4 and Week 6

Absolute values of systolic blood pressure and diastolic blood pressure Baseline (Day 1), Week 1, 2, 3, 4, and 6 as vital parameters were reported. Three measurements of systolic blood pressure and diastolic blood pressure were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff).

Time frame:
Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Reported as:
Mean · Millimeter mercury (mmHg)
Absolute Values of Systolic Blood Pressure and Diastolic Blood Pressure Baseline, Week 1, Week 2, Week 3, Week 4 and Week 6
Millimeter mercury (mmHg)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Systolic blood pressure, Day 1132.9 ± 14.57135.5 ± 13.50134.0 ± 16.96140.1 ± 15.50
Systolic blood pressure, Week 1132.3 ± 19.26136.0 ± 17.29134.6 ± 20.52137.8 ± 13.29
Systolic blood pressure, Week 2128.4 ± 12.39129.4 ± 19.45129.9 ± 17.18139.1 ± 14.69
Systolic blood pressure, Week 3130.2 ± 13.20133.5 ± 17.28133.0 ± 19.06131.7 ± 12.78
Systolic blood pressure, Week 4132.6 ± 13.94133.1 ± 21.50134.2 ± 14.21135.4 ± 12.97
Systolic blood pressure, Week 6134.3 ± 17.34131.7 ± 19.53135.0 ± 22.79130.4 ± 14.10
Diastolic blood pressure, Day 169.9 ± 11.7069.0 ± 9.4868.2 ± 8.0271.7 ± 10.03
Diastolic blood pressure, Week 166.9 ± 11.7268.8 ± 10.7267.4 ± 9.7271.5 ± 10.04
Diastolic blood pressure, Week 267.7 ± 13.0468.6 ± 10.1166.0 ± 8.7172.7 ± 12.65
Diastolic blood pressure, Week 367.7 ± 10.4169.5 ± 11.3966.5 ± 10.0966.9 ± 11.35
Diastolic blood pressure, Week 468.9 ± 12.4168.2 ± 11.9466.2 ± 7.2468.9 ± 10.68
Diastolic blood pressure, Week 670.3 ± 11.0467.2 ± 8.3366.6 ± 8.2670.1 ± 10.43
SecondaryChange From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at Week 1, 2, 3, 4, and 6

Three measurements of SBP and DBP were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff). Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in systolic blood pressure and diastolic blood pressure at Week 1, 2, 3, 4, and 6 were reported.

Time frame:
Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at Week 1, 2, 3, 4, and 6
mmHgPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Systolic blood pressure, Week 1-0.519 ± 12.40241.167 ± 7.18740.565 ± 13.6685-2.368 ± 8.9062
Systolic blood pressure, Week 2-3.373 ± 9.6414-5.786 ± 15.4381-5.284 ± 11.61171.241 ± 15.2259
Systolic blood pressure, Week 3-1.529 ± 13.8349-1.643 ± 9.4312-2.206 ± 13.4641-5.216 ± 13.0309
Systolic blood pressure, Week 40.854 ± 10.1463-0.944 ± 13.76930.844 ± 9.8529-1.510 ± 14.4554
Systolic blood pressure, Week 60.125 ± 15.6446-2.458 ± 15.85201.656 ± 17.5153-6.451 ± 15.9295
Diastolic blood pressure, Week 1-3.037 ± 8.64090.521 ± 7.5933-0.750 ± 7.5737-0.193 ± 6.9711
Diastolic blood pressure, Week 2-1.608 ± 12.0348-0.024 ± 8.0133-2.206 ± 9.06331.963 ± 7.1189
Diastolic blood pressure, Week 3-1.647 ± 8.79980.857 ± 8.1531-1.755 ± 7.8329-2.627 ± 7.5414
Diastolic blood pressure, Week 4-0.625 ± 5.9590-0.111 ± 8.8299-1.615 ± 7.8894-0.667 ± 7.2024
Diastolic blood pressure, Week 61.396 ± 7.9807-1.312 ± 10.6795-1.281 ± 7.77410.529 ± 8.0830
SecondaryAbsolute Values of Heart Rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6

Absolute values of heart rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6 were reported as vital parameter. Three measurements of heart rate were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff).

Time frame:
Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Reported as:
Mean · Beats per minute
Absolute Values of Heart Rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6
Beats per minutePlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Heart rate, Day 168.4 ± 10.7868.4 ± 8.0769.1 ± 14.5867.8 ± 7.53
Heart rate, Week 168.7 ± 10.3369.5 ± 8.7169.4 ± 12.8969.4 ± 9.80
Heart rate, Week 268.9 ± 8.9567.5 ± 7.6066.9 ± 13.0367.6 ± 11.46
Heart rate, Week 371.9 ± 9.9269.8 ± 10.5168.7 ± 14.4366.9 ± 11.96
Heart rate, Week 467.9 ± 9.5068.5 ± 9.5567.9 ± 16.2965.4 ± 11.97
Heart rate, Week 671.0 ± 10.6367.6 ± 9.2768.0 ± 10.5568.9 ± 13.01
SecondaryChange From Baseline in Heart Rate at Week 1, 2, 3, 4, and 6

Three measurements of heart rate were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff). Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. change from baseline in heart rate at Week 1, 2, 3, 4, and 6 were reported.

Time frame:
Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Reported as:
Mean · Beats per minute
Change From Baseline in Heart Rate at Week 1, 2, 3, 4, and 6
Beats per minutePlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Heart rate, Week 10.296 ± 7.10051.375 ± 6.90880.315 ± 12.58981.632 ± 7.1258
Heart rate, Week 20.412 ± 7.6771-1.310 ± 7.6051-1.333 ± 5.5777-0.500 ± 6.8716
Heart rate, Week 33.392 ± 8.35430.976 ± 8.31790.412 ± 6.6558-0.510 ± 6.9802
Heart rate, Week 4-1.167 ± 8.72711.111 ± 7.0801-0.500 ± 7.0889-2.020 ± 7.8391
Heart rate, Week 61.854 ± 10.9029-0.167 ± 7.7993-0.458 ± 8.28460.917 ± 7.5134
SecondaryAbsolute Electrocardiogram (ECG) Parameter Values at Baseline (Screening), Week 2, 4, and 6

Full 12-lead ECGs were recorded in participants who were rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. Full 12-lead ECGs were recorded on the provided ECG machine that automatically calculates heart rate, PR, QRS, QT and QTc intervals. Absolute ECG parameters including PR interval, QT interval and QRS duration values at Baseline (Screening), Week 2, 4, and 6 were reported.

Time frame:
Baseline (Screening), Week 2, 4, and 6
Reported as:
Mean · Milliseconds (msec)
Absolute Electrocardiogram (ECG) Parameter Values at Baseline (Screening), Week 2, 4, and 6
Milliseconds (msec)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
PR Interval, Day 1160.750 ± 31.1849164.727 ± 38.0430165.313 ± 29.3513177.630 ± 23.4002
PR Interval, Week 2165.961 ± 26.2271187.002 ± 38.5301172.909 ± 29.4006176.875 ± 24.4073
PR Interval, Week 4161.689 ± 33.5960180.000 ± 25.7034174.875 ± 29.2025176.000 ± 31.8927
PR Interval, Week 6153.914 ± 19.9718183.314 ± 42.9671175.321 ± 32.9893179.307 ± 31.1222
QRS Duration, Day 199.750 ± 14.9833101.227 ± 29.747199.532 ± 9.2023106.444 ± 20.6101
QRS Duration, Week 2107.647 ± 22.2899101.111 ± 19.1603102.328 ± 17.8897106.556 ± 21.4729
QRS Duration, Week 4101.467 ± 20.1127104.205 ± 22.4275103.965 ± 20.4125104.392 ± 25.2312
QRS Duration, Week 696.186 ± 14.2459104.729 ± 21.0227101.811 ± 18.7734105.617 ± 22.9352
Uncorrected QT Interval, Day 1412.000 ± 33.7554432.455 ± 37.7870405.541 ± 25.1111426.074 ± 25.1141
Uncorrected QT Interval, Week 2411.804 ± 40.7532422.837 ± 35.0150408.936 ± 33.1958419.444 ± 36.1943
Uncorrected QT Interval, Week 4413.111 ± 32.4499413.333 ± 34.7435411.859 ± 42.7345423.255 ± 44.3408
Uncorrected QT Interval, Week 6404.500 ± 34.8993428.077 ± 34.7094396.778 ± 32.4936417.686 ± 45.1037
QTc Interval (Bazett's), Day 1430.833 ± 21.5149446.712 ± 35.2019435.351 ± 30.0154437.593 ± 33.7848
QTc Interval (Bazett's), Week 2440.843 ± 25.7892440.390 ± 24.2664428.144 ± 28.4053431.500 ± 34.3464
QTc Interval (Bazett's), Week 4435.556 ± 23.1025434.590 ± 20.6551429.480 ± 31.0592426.549 ± 32.4467
QTc Interval (Bazett's), Week 6444.771 ± 23.8784441.622 ± 24.7866429.983 ± 30.9609431.700 ± 34.0017
QTc Interval (Fridericias's), Day 1424.417 ± 20.2310441.424 ± 31.0923424.970 ± 23.7320433.815 ± 28.8483
QTc Interval (Fridericias's), Week 2430.549 ± 26.2520434.178 ± 23.6892421.124 ± 22.9709426.944 ± 30.0734
QTc Interval (Fridericias's), Week 4427.711 ± 23.0747427.103 ± 20.4117422.943 ± 28.9082424.961 ± 32.3172
QTc Interval (Fridericias's), Week 6430.357 ± 22.9401436.666 ± 22.8305418.161 ± 24.9461426.591 ± 33.2459
SecondaryChange From Baseline in ECG Parameters at Week 2, 4 and 6

Full 12-lead ECGs were recorded in participants who were rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. Full 12-lead ECGs were recorded on the provided ECG machine that automatically calculates heart rate, PR, QRS, QT and QTc intervals. Baseline ECG values were defined as measurements taken at screening. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.

Time frame:
Baseline (Screening), Week 2, 4, and 6
Reported as:
Mean · msec
Change From Baseline in ECG Parameters at Week 2, 4 and 6
msecPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
PR Interval, Week 2-1.2 ± 9.223.6 ± 15.612.5 ± 9.88-0.6 ± 10.80
PR Interval, Week 4-2.6 ± 17.371.8 ± 9.973.1 ± 12.35-2.0 ± 16.16
PR Interval, Week 6-5.8 ± 10.700.5 ± 16.22-0.2 ± 16.831.3 ± 15.67
QRS Duration, Week 22.5 ± 7.69-0.0 ± 5.800.4 ± 7.294.6 ± 4.94
QRS Duration, Week 4-0.4 ± 13.821.8 ± 4.801.3 ± 5.322.3 ± 8.15
QRS Duration, Week 6-0.3 ± 8.070.2 ± 10.04-1.9 ± 6.643.5 ± 5.07
Uncorrected QT Interval, Week 2-10.8 ± 28.14-1.9 ± 12.253.1 ± 15.315.8 ± 22.23
Uncorrected QT Interval, Week 4-2.9 ± 21.31-10.9 ± 18.755.4 ± 17.878.8 ± 20.89
Uncorrected QT Interval, Week 6-7.9 ± 20.94-2.4 ± 17.34-6.7 ± 15.393.2 ± 31.45
QTc Interval (Bazett's), Week 27.9 ± 18.963.4 ± 11.28-4.0 ± 12.981.7 ± 17.77
QTc Interval (Bazett's), Week 42.5 ± 15.30-0.8 ± 10.26-1.8 ± 14.87-1.9 ± 19.04
QTc Interval (Bazett's), Week 611.4 ± 17.492.9 ± 12.940.0 ± 20.993.3 ± 19.38
QTc Interval (Fridericias's), Week 21.6 ± 12.031.7 ± 7.80-1.7 ± 10.683.0 ± 17.12
QTc Interval (Fridericias's), Week 41.0 ± 11.26-4.2 ± 10.160.5 ± 13.541.6 ± 17.45
QTc Interval (Fridericias's), Week 64.6 ± 12.041.0 ± 11.36-2.4 ± 15.053.2 ± 18.08
SecondaryMean Maximum Plasma Concentration (Cmax) of GSK1278863 and GSK1278863 Metabolites

Cmax of GSK1278863 and GSK1278863 metabolites (M1, M2, M3, M4, M5 and M6) were reported. For assessment of Pharmacokinetics parameters blood samples were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).

Time frame:
Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Mean Maximum Plasma Concentration (Cmax) of GSK1278863 and GSK1278863 Metabolites
nanogram per millilitre (ng/mL)GSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
GSK12788632.68 ± 92.612.8 ± 12135.7 ± 143
M21.03 ± 27.93.83 ± 61.410.3 ± 61.1
M31.23 ± 25.14.45 ± 54.411.8 ± 64.8
M40.721 ± 29.72.74 ± 84.77.29 ± 116
M50.296 ± 23.71.08 ± 49.02.81 ± 79.8
M60.455 ± 21.91.74 ± 56.14.43 ± 83.1
SecondaryMean Steady State Area Under the Curve (AUC) of GSK1278863 and GSK1278863 Metabolites

Mean Steady state AUC of GSK1278863 and GSK1278863 metabolites (M1, M2, M3, M4, M5 and M6) were reported. For pharmacokinetic parameter assessment blood samples were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this fist sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).

Time frame:
Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose)
Reported as:
Geometric mean · ng*hour/mL
Mean Steady State Area Under the Curve (AUC) of GSK1278863 and GSK1278863 Metabolites
ng*hour/mLGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
GSK127886310.3 ± 11951.1 ± 159148 ± 167
M213.0 ± 38.851.9 ± 81.3140 ± 65.4
M317.8 ± 33.467.1 ± 74.2175 ± 71.6
M45.54 ± 60.022.0 ± 99.063.4 ± 105
M54.64 ± 27.717.3 ± 66.743.5 ± 86.0
M65.34 ± 36.321.5 ± 71.456.3 ± 85.8

Adverse events

Collected over Up to follow up contact (Week 6).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/18 (0%)1/18 (5.6%)8/18 (44.4%)
GSK1278863, 0.5 mg0/17 (0%)0/17 (0%)10/17 (58.8%)
GSK1278863, 2 mg0/18 (0%)2/18 (11.1%)5/18 (27.8%)
GSK1278863, 5 mg0/19 (0%)1/19 (5.3%)5/19 (26.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
Renal failure acuteRenal and urinary disorders0/180/171/180/19
Pancreatitis acuteGastrointestinal disorders0/180/171/180/19
AppendicitisInfections and infestations1/180/170/180/19
HypoglycaemiaMetabolism and nutrition disorders0/180/171/180/19
AzotaemiaRenal and urinary disorders0/180/170/181/19
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mg
NauseaGastrointestinal disorders2/182/170/181/19
AstheniaGeneral disorders1/181/170/180/19
DizzinessNervous system disorders1/181/170/180/19
Muscle spasmsMusculoskeletal and connective tissue disorders0/181/170/181/19
Urinary tract infectionInfections and infestations1/181/170/180/19
VomitingGastrointestinal disorders0/181/170/181/19
Abdominal painGastrointestinal disorders0/181/170/180/19
Blood creatine phosphokinase increasedInvestigations0/181/170/180/19
Conduction disorderCardiac disorders0/181/170/180/19
ConstipationGastrointestinal disorders0/181/170/180/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mgTotal
Mean69.2 ± 11.0066.6 ± 11.7366.9 ± 11.4571.3 ± 11.2668.6 ± 11.28
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mgTotal
Female1412101652
Male458320
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGSK1278863, 0.5 mgGSK1278863, 2 mgGSK1278863, 5 mgTotal
Hispanic or Latino654520
Not Hispanic or Latino1212141452
Unknown or Not Reported00000
08

Study locations

55 sites
  • GSK Investigational Site
    Azusa, California 91702, United States
  • GSK Investigational Site
    Bakersfield, California 93309, United States
  • GSK Investigational Site
    Chino, California 91710, United States
  • GSK Investigational Site
    Los Angeles, California 90022, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Los Angeles, California 90057, United States
  • GSK Investigational Site
    North Hollywood, California 91606-1559, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Riverside, California 92505, United States
  • GSK Investigational Site
    San Dimas, California 91773, United States
  • GSK Investigational Site
    West Hills, California 91307, United States
  • GSK Investigational Site
    Yuba City, California, United States
  • GSK Investigational Site
    Denver, Colorado 80230, United States
  • GSK Investigational Site
    Daytona Beach, Florida 32117, United States
  • GSK Investigational Site
    Edgewater, Florida 32132, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Jacksonville, Florida 32258, United States
  • GSK Investigational Site
    Miami, Florida 33145, United States
  • GSK Investigational Site
    Miami, Florida 33150, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Ocala, Florida 34471, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33028, United States
  • GSK Investigational Site
    Port Charlotte, Florida 33952, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Evanston, Illinois 60201, United States
  • GSK Investigational Site
    Gurnee, Illinois 60031, United States
  • GSK Investigational Site
    Detroit, Michigan 48236, United States
  • GSK Investigational Site
    Asheville, North Carolina 28801, United States
  • GSK Investigational Site
    Charlotte, North Carolina, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73116, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Bethlehem, Pennsylvania 18017, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16507, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Arlington, Texas 76011, United States
  • GSK Investigational Site
    Austin, Texas 78751, United States
  • GSK Investigational Site
    Corsicana, Texas 75110, United States
  • GSK Investigational Site
    Greenville, Texas 75402, United States
  • GSK Investigational Site
    Houston, Texas 77054, United States
  • GSK Investigational Site
    Houston, Texas 77099, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Temple, Texas 76502, United States
  • GSK Investigational Site
    Silverdale, Washington 98383, United States
  • GSK Investigational Site
    Calgary, Alberta T2R 0X7, Canada
  • GSK Investigational Site
    Brampton, Ontario L6T 0G1, Canada
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
  • GSK Investigational Site
    Sudbury, Ontario P3E 5J1, Canada
  • GSK Investigational Site
    Heidelberg, Baden-Wuerttemberg 69120, Germany
  • GSK Investigational Site
    Aschaffenburg, Bayern 63741, Germany
  • GSK Investigational Site
    Demmin, Mecklenburg-Vorpommern 17109, Germany
  • GSK Investigational Site
    Lehrte, Niedersachsen 31275, Germany
  • GSK Investigational Site
    Hamburg, 22297, Germany
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, Lepore JJ, Cobitz AR. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. J Am Soc Nephrol. 2016 Apr;27(4):1234-44. doi: 10.1681/ASN.2014111139. Epub 2015 Oct 22. PubMed 26494831 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in May 2013, 11 months.

Results were first posted in Nov 2017, 4 years 6 months after primary completion. A results delay was requested in Apr 2015.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 11 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2012
First posted
Apr 30, 2012
StartActual
May 17, 2012
Primary completionActual
May 7, 2013
CompletionActual
May 7, 2013
Results delay requested
Apr 27, 2015
Results first posted
Nov 9, 2017
Last update
Nov 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01587898
Lead sponsor
GlaxoSmithKline
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Apr 30, 2012
Start date
May 17, 2012
Primary completion
May 7, 2013
Completion
May 7, 2013
Results posted
Nov 9, 2017
Last update
Nov 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion